Six well-known dividend-paying companies, including Pfizer, Icahn Enterprises, and Western Union, have been distributing dividends exceeding their net income and operating cash flow for multiple years. This practice often relies on borrowing, which is unsustainable long-term and signals potential dividend cuts ahead. Investors should carefully review cash flow statements to avoid high yields that mask financial weakness. The article highlights the importance of assessing dividend safety beyond yield alone, as continued payouts without sufficient earnings can lead to significant share price declines when cuts occur.
As of Oct 07, 2026 18:11 WIB, Pfizer (PFE) trades on Pluang at USD 27.68 with a 1-day gain of 0.71%. Despite the article's warning on unsustainable dividends, Pfizer's dividend yield remains high at 6.25%. Pluang data also shows a market cap of $156.74 billion and a typical hold time of 157 days, indicating steady investor interest.
Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...
Moderna's stock has soared 545% year-to-date, driven by its mRNA technology and a promising oncology pipeline including a personalized cancer vaccine. The company now joins the NASDAQ 100, increasing its visibility and institutional interest. Despite...
Vaccine stocks surged after a Siberian plague scare, but health officials have since declared the risk low, causing Novavax shares to drop 2% after a prior 20% spike. Novavax's rally was driven by speculation of government vaccine purchases, but the ...
Moderna shares surged 8% to $204.60 as investors anticipate the full Phase 3 melanoma vaccine trial data to be presented at the European Society for Medical Oncology (ESMO) congress in Madrid. The vaccine, developed with Merck, showed promising resul...
